This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
Private-equity acquisitions of primary-care provider practices neither alter hospitalization rates nor affect acute-care outcomes, according to new research out of Brown University.
If Congress doesn’t act soon, CMS’s flexible funding of telemedicine visits—a temporary holdover from the COVID era—will dry up next year. A new study may help persuade fiscally cautious representatives not to let that happen.
Agentic large-language models can draft hospital discharge summaries that are safe, useful and demonstrably effective at helping to curb physician burnout, according to research conducted at Stanford University.
Heparin-induced thrombocytopenia after heart surgery is a major concern, but prior guidelines were developed without much feedback from actual cardiac surgeons.
Family physicians and other primary care providers don’t mind being held to account for care quality by healthcare administrators. The rub is that multiple other stakeholders often demand similar levels of answerability, pulling the doctors in different directions at once.
The Society of Thoracic Surgeons put together an expert committee to examine the prevention and treatment of new-onset postoperative atrial fibrillation after cardiac surgery. The group shared recommendations for before, during and after treatment.
Pharmaceutical companies are spending close to $10 billion per year on direct-to-consumer advertising in the U.S. Only the entertainment industry spends more. Is that a good thing?
Heart Rhythm 2026 in Chicago will include a total of 18 late-breaking clinical trials—and that is just the beginning. The four-day event kicks off April 23.
Of all lawsuits filed against patients in 2024 in one U.S. state, physician practices and other non-hospital healthcare entities accounted for 80% of cases. That’s a complete inversion from just six years prior.
In the three or so years since it burst into healthcare, ambient AI scribe technology has run away with the win in the market-uptake race. What has been the return on investment in all those software packages?